KMK Consulting Inc.

As we mark Lung Cancer Awareness Month, we recognize both the progress made and the critical gaps that persist in real-world outcomes for patients.   One of our real-world evidence studies evaluated overall survival in individuals with EGFR-mutated advanced NSCLC receiving first-line targeted therapy, using data from three major U.S. oncology databases (ConcertAI, Flatiron Health, and COTA).   Compared with clinical trial results, real-world survival outcomes were substantially lower: 🔹 Median overall survival: 27.7–29.2 months 🔹 24-month survival: 57–60% 🔹 26–32% of patients did not survive long enough to initiate second-line therapy   Higher-risk factors included older age, CNS or liver metastases, TP53 co-mutations, the L858R subtype, and ECOG ≥2.   These findings underscore the ongoing gap between clinical trial efficacy and real-world patient experience and highlight the urgent need to accelerate therapeutic innovation, optimize treatment pathways, and close the survival gap for people facing EGFR-driven lung cancer.   A special shout-out to KMK author Anne (Yen-Hua) Chen for her impactful contributions to this important work.   Read the full abstract here: https://lnkd.in/dyc8CPNc Connect with us to learn more about our oncology RWE expertise: https://lnkd.in/dg7sQPqy   #KMKConsulting #LungCancerAwarenessMonth #LungCancer #NSCLC #EGFR #Oncology #RealWorldEvidence #CancerResearch #DataDrivenInsights

Welcome aboard Anvesh Gorli ! We’re excited to have you join us as a Senior Associate and are confident that your dedication and potential will play a key role in our shared success.

Welcome aboard Kevin Bradley ! We’re excited to have you join us as a Senior Associate and are confident that your dedication and potential will play a key role in our shared success.

Proud to share that KMK is now Great Place to Work® certified! 🌟 This milestone celebrates our continuous commitment to empowering people, nurturing trust, and building a workplace where every idea matters. Together, we’re not just a team — we’re a community driving excellence every day. #KMK #Datadrivensuccess #GreatPlaceToWork #KMKTeam #CompanyCulture #PeopleFirst #KMKLife #InspiringWorkplace #TogetherWeGrow

We’re excited to announce that our latest research on the economic burden of neutropenia in metastatic breast cancer (mBC) has been accepted for poster presentation at AMCP Nexus 2025 (October 27–30)!   Using the IQVIA PharMetrics® Plus claims database (2019–2024), this retrospective study analyzed U.S. patients with HR+/HER2- and triple-negative mBC. Findings revealed that neutropenia is a common complication, particularly with current treatment regimens, leading to increased healthcare resource utilization and higher overall costs. These insights underscore the urgent need for treatments that reduce toxicity while preserving efficacy, ultimately aiming to improve care outcomes and reduce economic strain.   Attending AMCP Nexus this year? Don't miss our poster presentation, co-authored by KMK and Yulin Shi titled - “Economic burden of neutropenia among patients treated for HR+/HER2- and triple-negative metastatic breast cancer in the United States: a retrospective claims analysis”, and join the dialogue on driving smarter, more sustainable oncology care.   For More Details: https://lnkd.in/dBVB8nxg Our Publications: Https://https://lnkd.in/dErzpWQ6    #KMKConsulting #RWE #BreastCancerAwareness #Neutropenia #MetastaticBreastCancer #AMCPNexus2025 #HealthEconomics #OncologyResearch #ValueBasedCare #DataDrivenInsights

We’re excited to announce that our latest research on the economic burden of neutropenia in metastatic breast cancer (mBC) has been accepted for poster presentation at AMCP Nexus 2025 (October 27–30)!   Using the IQVIA PharMetrics® Plus claims database (2019–2024), this retrospective study analyzed U.S. patients with HR+/HER2- and triple-negative mBC. Findings revealed that neutropenia is a common complication, particularly with current treatment regimens, leading to increased healthcare resource utilization and higher overall costs. These insights underscore the urgent need for treatments that reduce toxicity while preserving efficacy, ultimately aiming to improve care outcomes and reduce economic strain.   Attending AMCP Nexus this year? Don't miss our poster presentation, co-authored by KMK and Yulin Shi titled - “Economic burden of neutropenia among patients treated for HR+/HER2- and triple-negative metastatic breast cancer in the United States: a retrospective claims analysis”, and join the dialogue on driving smarter, more sustainable oncology care.   For More Details: https://lnkd.in/dBVB8nxg Our Publications: Https://https://lnkd.in/dErzpWQ6    #KMKConsulting #RWE #BreastCancerAwareness #Neutropenia #MetastaticBreastCancer #AMCPNexus2025 #HealthEconomics #OncologyResearch #ValueBasedCare #DataDrivenInsights

Proud to share our recently published study in JBMR Plus, examining diagnostic patterns in children with X-linked hypophosphatemia (XLH) across North America, South America, Europe, and Israel. Key findings from our analysis of 666 children include: - Children with a family history of XLH were diagnosed at younger ages than those without - Despite family history, diagnosis was often delayed beyond age 1 - Earlier recognition is critical for timely treatment and improved outcomes These findings highlight the need for increased awareness of XLH symptoms to reduce diagnostic delays and improve long-term patient care. Kudos to KMK author Shubham Tewari for his impactful contributions to this important research!   https://lnkd.in/dF2SEAp9   At KMK, we specialize in generating actionable real-world evidence (RWE) but not limited to: - Validate clinical and economic value—especially in rare diseases - Highlight disease burden and unmet medical need - Strengthen stakeholder engagement (e.g., with payers, clinicians, and patient advocacy groups) - Support publication strategies   Our Publications: https://lnkd.in/dFvKUpbq   Contact Us: https://lnkd.in/dg7sQPqy   #KMKConsulting #RWE #RareDiseases #XLH #PediatricResearch #BoneHealth #HealthOutcomes #DataDrivenInsights

💗 Myths Don’t Save Lives — Awareness Does From “it only happens to older women” to “men can’t get breast cancer” — myths still cloud the truth. Let’s break the silence, bust the myths, and spread real awareness this Breast Cancer Awareness Month. Together, we can make a difference. 🎗️ #KMK #Actionableinsights #Datadrivensuccess #BreastCancerAwareness #MythVsFact #PinkOctober #BreastHealthAwareness #CancerMyths #OncologyAwareness

More than lights, Diwali is about the moments that bring families closer. 🪔 Here’s to shared laughter, good food, and new memories made together. #KMK #Actionableinsights #Datadrivensuccess #DiwaliVibes #FestivalOfLights #Hope #GoodVibes #Tradition #India #Prosperity

Grateful to all our incredible alumni who made the KMK Alumni Event truly special! 🌟 It was wonderful reconnecting, reminiscing, and celebrating the KMK spirit together. 💙 #KMK #Datadrivensuccess #KMKAlumni #AlumniEvent #Gratitude #KMKFamily #ReunionMoments #StrongerTogether #MemoriesForever #KMKCommunity